Liquid biopsy for early cancer detection: novel approaches show promising early signals
Novel tests based on epitranscriptomics and cfCTCF-DNA nucleoproteins aim to overcome sensitivity limitations of currently available methods
Treatment duration of immunotherapy combination does not impact on disease-free survival in dMMR colon cancer
An ATOMIC study pre-planned exploratory analysis reports no DFS benefit with the addition of immunotherapy in patients receiving fewer than six cycles of chemotherapy
Adagrasib plus cetuximab fails to outperform chemotherapy in KRAS G12C-mutated metastatic colorectal cancer
The phase III KRYSTAL-10 trial did not meet its co-primary survival endpoints
Novel data support the use of liquid biopsy to guide cetuximab rechallenge in metastatic colorectal cancer
Tumours with no ctDNA-identified pathogenic variants for anti-EGFR drug resistance genes appear to respond to continued cetuximab beyond disease progression
Optimal sequencing of immunotherapy in MSI-H/dMMR colon cancer remains uncertain
In light of recent evidence from the ATOMIC trial, balancing adjuvant and neoadjuvant immunotherapy approaches continues to challenge clinical decision-making.
Structured exercise enters ESMO guidelines for colon cancer as recommended treatment
The update reflects survival benefits of post-diagnosis exercise in stage II–III colon cancer as recently reported in the CHALLENGE study
Next-generation KRAS G12C inhibitor shows promising activity in advanced colorectal cancer
Manageable safety and encouraging antitumour responses were presented with MK-1084 monotherapy and combination regimens
ctDNA-guided adjuvant chemotherapy in colon cancer: not ready for prime time?
Two studies fail to meet their primary endpoints, reinforcing the need to improve the sensitivity of ctDNA testing before it enters the clinic
First-in-human trial of a TCR-T therapy targeting KRAS G12V reports a significant response rate
Preliminary results of NW-301V are promising, with a lack of severe adverse effects at all doses tested in patients with pancreatic cancer or colorectal cancer
Zanzalintinib plus atezolizumab shows activity in metastatic colorectal cancer with microsatellite stable disease
Primary phase III overall survival analysis suggests that the combination therapy may be a potential new option for previously treated patients with or without liver metastases